Research Article
Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
Table 1
Cohort characteristics.
| | Number of patients | 36 | | Median age in years (IQR) | 69.7 (58.8–76.8) | | Median follow-up for entire cohort in months (IQR) | 16.8 (9.3–38.7) | | Gender | | | Male | 30 (83%) | | Female | 6 (17%) | | Race | | | Caucasian | 32 (88.8%) | | Other | 4 (11.2%) | | Urothelial cell carcinoma variant | | | None | 14 (38.9%) | | Small cell | 9 (25.0%) | | Micropapillary | 5 (13.9%) | | Other* | 5 (13.9%) | | Not available | 3 (8.3%) | | Prechemotherapy clinical stage | | | cT2 | 22 (61.1%) | | cT3 | 10 (27.7%) | | cT4 | 2 (5.6%) | | Not available | 2 (5.6%) | | Prechemotherapy carcinoma in situ | | | Present | 21 (58.3%) | | Not present | 12 (33.3%) | | Not available | 3 (8.3%) | | Prechemotherapy clinical nodal status | | | cN0 | 28 (77.8%) | | cN+ | 6 (16.7%) | | Not available | 3 (5.6%) | | Chemotherapy regimen | | | Gemcitabine and cisplatin | 20 (55.5%) | | Etoposide and cisplatin | 7 (19.4%) | | Paclitaxel, ifosfamide, and cisplatin | 3 (8.3%) | | Methotrexate, vinblastine, doxorubicin, and cisplatin | 2 (5.6%) | | Other | 3 (8.3%) | | Not available | 1 (2.8%) | | Postchemotherapy clinical stage | | | cT0 | 21 (58.3%) | | cTis | 3 (8.3%) | | cT1 | 1 (2.7%) | | cT2 | 6 (16.7%) | | cT3 | 2 (5.6%) | | cT4 | 1 (2.8%) | | Not available | 2 (5.6%) | | Postchemotherapy CIS | | | Present | 5 (13.9%) | | Not present | 26 (72.2%) | | Not available | 5 (13.9%) | | Postchemotherapy clinical nodal status | | | cN0 | 31 (86.1%) | | cN+ | 4 (11.1%) | | Not available | 1 (2.8%) | | Postchemotherapy median follow-up in months (IQR)∧ | | | cT0 | 17.8 (12.8–34.3) | | >cT0 | 16.8 (4.4–43.1) | | Final pathologic stage | | | pT0 | 18 (50.0%) | | pTis | 6 (16.7%) | | pT1 | 2 (5.6%) | | pT2 | 3 (8.3%) | | pT3 | 7 (19.4%) | | Final pathology carcinoma in situ | | | Present | 14 (38.9%) | | Not present | 22 (61.1%) | | Not available | 0 (0%) | | Final pathologic nodal involvement | | | pN0 | 27 (75.0%) | | pN+ | 4 (11.1%) | | Not available | 5 (13.9%) | | Surgical margin (SM) | | | SM− | 15 (41.7%) | | SM+ | 3 (8.3%) | | NA (pT0) | 18 (50.0%) |
|
|
Other urothelial cell carcinoma variants include glandular (2) and plasmacytoid (2).
∧No difference in median follow-up by rank sum test, .
|
